Samantha Hocking
Overview
Explore the profile of Samantha Hocking including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
297
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Frampton R, Snaith J, Hocking S, Holmes-Walker J, Olsen N, Greenfield J
Diabet Med
. 2024 Jun;
41(10):e15377.
PMID: 38853340
Background: Premature cardiovascular disease is the leading cause of death in people living with type 1 diabetes. Therapies are urgently needed to address cardiovascular risk in this group. Semaglutide, a...
2.
3.
OHara D, Lam C, McMurray J, Yi T, Hocking S, Dawson J, et al.
Nat Rev Nephrol
. 2024 Apr;
20(8):513-529.
PMID: 38671190
Sodium-glucose cotransporter 2 (SGLT2) inhibitors were initially developed for their glucose-lowering effects and have shown a modest glycaemic benefit in people with type 2 diabetes mellitus (T2DM). In the past...
4.
MacIsaac R, Deed G, dEmden M, Ekinci E, Hocking S, Sumithran P, et al.
Diabetes Ther
. 2023 Oct;
14(12):1997-2014.
PMID: 37824027
Tirzepatide is a first-in-class GIP/GLP-1 receptor agonist ('twincretin')-a single molecule that acts as an agonist at both glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. In the SURPASS...
5.
Susanto A, Fuller N, Hocking S, Markovic T, Gill T
Clin Obes
. 2023 May;
13(5):e12604.
PMID: 37248784
Males are under-represented in weight loss clinical trials, usually comprising fewer than one-quarter of participants. Our study aimed to investigate people's motivations for participating in weight loss trials and determine...
6.
Hocking S, Sumithran P
Rev Endocr Metab Disord
. 2023 May;
24(5):951-960.
PMID: 37202547
Obesity continues to increase in prevalence globally, driven by changes in environmental factors which have accelerated the development of obesity in individuals with an underlying predisposition to weight gain. The...
7.
Franklin R, Franklin J, Swinbourne J, Manson E, Loughnan G, Markovic T, et al.
Aust N Z J Public Health
. 2023 Jan;
47(1):100008.
PMID: 36640630
Objective: Obesity and injury are major inter-related public health challenges. The objective of this study was to explore the perceptions of injury in people with severe obesity. Methods: A cross-sectional...
8.
Davis S, Hocking S, Watt M, Gunton J
Obesity (Silver Spring)
. 2022 Dec;
31(1):7-19.
PMID: 36479639
Objective: The goal of this study was to review the metabolic effects of fat transplantation. Methods: Fat (adipose tissue [AT]) transplantation has been performed extensively for many years in the...
9.
Tham K, Abdul Ghani R, Cua S, Deerochanawong C, Fojas M, Hocking S, et al.
Obes Rev
. 2022 Dec;
24(2):e13520.
PMID: 36453081
Obesity is a chronic disease in which the abnormal or excessive accumulation of body fat leads to impaired health and increased risk of mortality and chronic health complications. Prevalence of...
10.
Franklin J, Sim K, Swinbourne J, Maston G, Manson E, Nelthorpe H, et al.
Clin Obes
. 2022 Nov;
13(2):e12567.
PMID: 36370062
Lockdown measures due to coronavirus-19 disease (COVID-19) have impacted lifestyle factors. This study aimed to explore whether health and lifestyle behaviours changed during the 2020 COVID-19 lockdown among patients with...